Vulnerabilities of Mutant SWI/SNF Complexes in Cancer  by Helming, Katherine C. et al.
Cancer Cell
ReviewVulnerabilities of Mutant
SWI/SNF Complexes in CancerKatherine C. Helming,1,2,3,4,5 Xiaofeng Wang,1,2,3,5 and Charles W.M. Roberts1,2,3,*
1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2Division of Hematology/Oncology, Boston Children’s Hospital, Boston, MA 02215, USA
3Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA
4Biological and Biomedical Sciences Program, Harvard Medical School, Boston, MA 02115, USA
5Co-first author
*Correspondence: charles_roberts@dfci.harvard.edu
http://dx.doi.org/10.1016/j.ccr.2014.07.018
Cancer genome sequencing efforts have revealed the novel theme that chromatin modifiers are frequently
mutated across a wide spectrum of cancers. Mutations in genes encoding subunits of SWI/SNF (BAF) chro-
matin remodeling complexes are particularly prevalent, occurring in 20% of all human cancers. As these are
typically loss-of-function mutations and not directly therapeutically targetable, central goals have been to
elucidate mechanism and identify vulnerabilities created by these mutations. Here, we discuss emerging
data that thesemutations lead to the formation of aberrant residual SWI/SNFcomplexes that constitute a spe-
cific vulnerability and discuss the potential for exploiting these dependencies in SWI/SNF mutant cancers.SWI/SNF complexes are evolutionarily conserved multisubunit
complexes that utilize the energy of ATP hydrolysis to mobilize
nucleosomesand remodel chromatin (Kassabovet al., 2003;Phe-
lan et al., 1999). These2MDa complexes aremade up of 12–15
subunits; they contain one of the two catalytic ATPase sub-
units, SMARCA4/BRG1 or SMARCA2/BRM; several core sub-
units, including SMARCB1/SNF5/INI1/BAF47 and SMARCC1/
BAF155, that are present in all SWI/SNF complexes; and subunits
present in only some variants, such as ARID1A and ARID1B,
mutually exclusive subunits for BAF (BRG1-associated factor)
varieties of the complexes, and PBRM1 and ARID2, specific for
PBAF (polybromo BRG1-associated factor) varieties of the com-
plexes (Wang et al., 1996; Wu et al., 2009). SWI/SNF complexes
interactwith transcription factors, coactivators, and corepressors
and are capable of mobilizing nucleosomes at target promoters
and enhancers to modulate gene expression (Figure 1) (Hu
et al., 2011; Tolstorukov et al., 2013; You et al., 2013) and have
also been implicated in various types of DNA repair (Dykhuizen
et al., 2013; Gong et al., 2006; Hara and Sancar, 2002; Park
et al., 2006; Watanabe et al., 2014).
With respect to a role in the control of gene expression, SWI/
SNF complexes have been shown to serve roles in the transcrip-
tional regulation of lineage specification and development in
numerous model systems. For example, SWI/SNF complexes
contribute to the development of T cells (Chi et al., 2002; Wang
et al., 2011b), hepatocytes (Gresh et al., 2005), oligodendrocytes
(Yu et al., 2013), and embryonic stemcell self-renewal and plurip-
otency (Gao et al., 2008; Ho et al., 2009). Specificity of SWI/SNF
complexes in the control of these developmental programs is
achieved in part through restricted expression and combinatorial
assembly of variant SWI/SNF subunits. The SMARCD3 (BAF60C)
subunit is expressed specifically in the embryonic heart, where it
is essential for the control of cardiac development (Lickert et al.,
2004). Similarly, a switch from the PHF10 (BAF45A) and ACTL6A
(BAF53A) subunits, which are expressed in neural stem cells, to
DPF1 (BAF45B), DPF3 (BAF45C), and ACTL6B (BAF53B) sub-units is essential to control the transition of neural progenitors
into postmitotic mature neurons (Lessard et al., 2007; Wu et al.,
2007). Such switching can modulate interaction with specific
transcription factors (Kadam et al., 2000) and facilitates differen-
tial activation of transcriptional pathways. Ultimately, via combi-
natorial inclusion of variant subunits, several hundred versions of
SWI/SNF complexes may exist (Wu et al., 2009) and serve
instructive roles in the control of fate specification.
The first clue linking SWI/SNF complexes to cancer came
in the late 1990s, when mutations of the gene encoding the
SMARCB1 (SNF5/INI1/BAF47) subunit were identified in rhab-
doid tumors (RTs), a rare but highly aggressive type of cancer
that strikes young children (Biegel et al., 1999; Versteege et al.,
1998). Smarcb1 was subsequently validated as a bona fide
and potent tumor suppressor in genetically engineered mouse
models (Guidi et al., 2001; Klochendler-Yeivin et al., 2000; Rob-
erts et al., 2000, 2002). While this observation was first noted
over a decade ago, it is only more recently via cancer genome
sequencing studies that the high prevalence of SWI/SNF subunit
mutations have been found in many types of cancer. At least
nine genes encoding subunits of SWI/SNF complexes have
been identified as recurrently mutated in cancers derived from
nearly every tissue in the body, collectively occurring in 20% of
all human cancers (Figure 1) (Kadoch et al., 2013; Shain and
Pollack, 2013). For example, inactivating mutations of ARID1A
are prevalent in a wide variety of cancers, including 45% of
ovarian clear cell and endometrioid carcinomas (Jones et al.,
2010; Wiegand et al., 2010); 19% of gastric cancers (Wang
et al., 2011a); 19% of bladder cancers (Gui et al., 2011); 14%
of hepatocellular cancers (Guichard et al., 2012); 12% of mela-
nomas (Hodis et al., 2012); and also less frequently in colorectal,
lung, breast, pancreas, and several other cancer types (Kadoch
et al., 2013; Shain and Pollack, 2013). SMARCA4 (BRG1), a cat-
alytic ATPase and a core subunit of SWI/SNF complexes, is
mutated in several cancer types, including lung (Medina et al.,
2008; Reisman et al., 2003), medulloblastoma (Parsons et al.,Cancer Cell 26, September 8, 2014 ª2014 Elsevier Inc. 309
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Figure 1. SWI/SNF Complexes Modulate
Transcription andGenes Encoding Subunits
of SWI/SNF Complexes Are Mutated in
Cancer
SWI/SNF complexes are found in two major
subtypes, BAF and PBAF, and comprise multiple
subunits (top left). SWI/SNF complexes contribute
to transcription modulation by mobilizing nucleo-
somes and by interacting with transcription fac-
tors, coactivators, and corepressors on DNA.
Subunits found mutated in cancer are denoted by
a red star and are described in the table (top right).
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Review2011), pancreatic cancer (Wong et al., 2000), and, most recently,
small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
(Jelinic et al., 2014; Ramos et al., 2014; Witkowski et al., 2014).
Other subunits have also been found to be mutated in cancer,
such as PRBM1 (BAF180) in renal carcinoma (Varela et al.,
2011) and ARID2 in melanoma (Hodis et al., 2012) and hepato-
cellular carcinoma (Li et al., 2011) (Figure 1). The mechanisms
by which mutation of each individual subunit promote oncogen-
esis and the function of mutated SWI/SNF complexes in cancer
is now an active area of investigation.
Many studies have elucidated pathways that are regulated by
SWI/SNF complexes and how disruption of these gene expres-
sion programs by subunit mutation promotes cancer. For
example, SWI/SNF can bind to retinoblastoma (RB) and facilitate
repression of RB target genes (Trouche et al., 1997). SWI/SNF
also interacts with MYC, both as an activator and as a repressor
(Cheng et al., 1999; Nagl et al., 2006). In part, via disruption of RB
function, inactivation of SMARCB1 leads to downregulation of
p16INK4a and E2F targets, indicating that SWI/SNF plays a role
in cell cycle regulation and differentiation (Betz et al., 2002; Isak-
off et al., 2005; Oruetxebarria et al., 2004). Additionally, SWI/SNF
complexes are required for specific regulation of interferon beta
targets (Morozov et al., 2007; Ramirez-Carrozzi et al., 2009).
It has been shown that SWI/SNF complexes can bind to the pro-
moters of roughly one-third of all genes (Ho et al., 2009; Tolstor-
ukov et al., 2013) and the aforementioned represent only a few
of numerous pathways that have been shown to be SWI/SNF
dependent.
With respect to the chromatin mechanisms that underlie regu-
lation of targets, a largely antagonistic functional relationship be-
tween SWI/SNF and PRC2 complexes has been identified (Ho
et al., 2009; Kennison and Tamkun, 1988; Kia et al., 2008; Wilson
et al., 2010). Loss of SMARCB1 leads to upregulation of EZH2
as well as broad H3K27 trimethylation and repression of PRC2
targets, effects that are essential for cancer formation driven
by SMARCB1 loss (Wilson et al., 2010). Targeted inhibition of310 Cancer Cell 26, September 8, 2014 ª2014 Elsevier Inc.EZH2 may represent a therapeutic op-
portunity for SMARCB1 mutant cancers
(Knutson et al., 2013). While the mecha-
nisms by which SWI/SNF mutations
contribute to cancer are still being eluci-
dated and the relative importance of con-
tributions to transcriptional regulation
versus DNA repair are still in question,
mutation of SWI/SNF subunits in cancer
likely contributes to cancer, at least inpart, by perturbing the regulation of transcriptional pathways
involved in control of proliferation and fate specification (Eroglu
et al., 2014).
It is interesting to note that, while loss-of-function SWI/SNF
subunit mutations seem most prevalent in cancer, point muta-
tions have also been described, such as a small number of
SMARCA4 missense mutations in medulloblastoma (Parsons
et al., 2011). It is not yet understood whether these point muta-
tions also result in loss of function of the protein, as in a classical
tumor suppressor, or whether they result in partial loss, or even
potentially oncogenic gain-of-function effects. Looking forward,
elucidating the effects of these point mutations will likely provide
further mechanistic understanding of the cancer-promoting
activity of SWI/SNF mutations. However, from a therapeutic
standpoint, as mutations in genes encoding SWI/SNF complex
subunits are often loss of function, including nonsense, frame-
shift, and large deletions (Lee et al., 2012; Versteege et al.,
1998; Wang et al., 2014b; Wilson and Roberts, 2011), the prod-
ucts of the mutant genes themselves do not constitute obvious
drug targets. Consequently, it is of great interest to identify spe-
cific vulnerabilities conferred by these mutations on cancer cells
that have the potential to provide new therapeutic opportunities.
The Residual Complex: A New Class of Vulnerability
One attractive hypothesis to account for many subunits of a sin-
gle complex mutated is that all of the mutations are essentially
equivalent and result in inactivation of SWI/SNF complexes.
However, several findings seemed in conflict with such a possi-
bility. First, the consequences of inactivation of genes encoding
SWI/SNF subunits in mice are fairly distinct. For example, while
inactivation of Smarcb1 and Smarca4 both result in early embry-
onic lethality at embryonic day (E)3.5 (Guidi et al., 2001; Klochen-
dler-Yeivin et al., 2000), knockout of Arid1a leads to the absence
of mesoderm and arrest at E6.5 (Gao et al., 2008), silencing of
Smarcd3 results in heart developmental defects (Lickert et al.,
2004), and Smarca2-deficient mice are viable (Reyes et al.,
Cancer Cell
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mental phenotypes. Second, loss of different subunits of the
complexes is associated with different types of cancer. For
example ARID1A is frequently mutated in ovarian cancer (Jones
et al., 2010; Wiegand et al., 2010); SMARCA4, in lung cancer
(Fukuoka et al., 2004; Medina et al., 2008; Reisman et al.,
2003); PBRM1, in renal cancer (Varela et al., 2011); and
SMARCB1, in RTs (Lee et al., 2012), with only modest overlap,
suggesting distinct consequences for mutation of different
subunits. Consistent with this, conditional Smarcb1 deletion in
mice results in formation of rhabdoid-like tumors and lym-
phomas (Roberts et al., 2002) while Smarca4 haploinsufficiency
leads to mammary tumors (Bultman et al., 2008). Third, it has
been shown that SWI/SNF complexes can assemble without
SMARCB1 (Doan et al., 2004), SMARCA4 (Hoffman et al.,
2014; Wilson et al., 2014), or ARID1A (Helming et al., 2014), indi-
cating that residual complexes remain despite tumor suppressor
subunit loss. Consequently, an alternate hypothesis was pro-
posed: that loss of tumor suppressor subunits results in aberrant
residual complexes that, in turn, actively drive oncogenesis
(Wang et al., 2009). Essentially, oncogenesis was not due to
tumor suppressor loss per se but rather to gain of aberrantly
functioning residual complexes.
Consistent with this hypothesis was the demonstration of an
essential role for the residual complex in driving cancer formation
in SMARCB1 mutant cancers. Specifically, rather than acceler-
ating cancer, or having no effect due to redundancy, the prolifer-
ation of SMARCB1-deficient human RT lines was blocked on
knockdown of SMARCA4, itself a tumor suppressor. In geneti-
cally engineered mouse models, inactivation of Smarca4 also
blocked the in vivo tumor formation otherwise caused by
Smarcb1 loss (Wang et al., 2009). These findings suggested
that the functional activity of residual SWI/SNF complexes might
be essential for cancer driven by SMARCB1 loss. However,
SMARCB1 mutant cancers are quite rare, and whether this
concept was similarly true for cancers mutant in other SWI/
SNF subunits was unknown. Additionally, since several SWI/
SNF subunits serve important roles in various cell types, it re-
mained unclear whether there was a differential requirement
for these subunits between SWI/SNF mutant cancers and
normal cells, which would be necessary for a potential therapeu-
tic approach based on targeted inhibition of residual complexes.
Recently, data from three large-scale screening publications
(Helming et al., 2014; Hoffman et al., 2014; Wilson et al., 2014)
have provided some insight to this question; they suggest that
an essential role for the residual complex extends to the wide
spectrum of cancers harboring mutations in other subunits and
also suggest that enhanced dependence on at least some resid-
ual complex members occurs in SWI/SNF mutant cancers. Proj-
ect Achilles is a near-genome-scale small hairpin RNA screen
against 11,000 genes performed in over 200 human cancer cell
lines (Cheung et al., 2011). Data from Project Achilles were
used to search for dependencies created by SWI/SNF mutation.
Within the cell lines in Project Achilles, genes encoding two SWI/
SNF subunits were mutated at sufficient frequency to enable a
search for vulnerabilities. ARID1A was mutant in 18 of 165 cell
lines, while SMARCA4 was mutant in 8 of 165 cell lines. Both
of these comparisons resulted in novel insights—in both cases,
the number one dependence was on a related SWI/SNF subunit.In ARID1A mutant cancer cells, ARID1B was identified as
the number one dependency, suggesting that, in the setting of
ARID1Amutation, residual SWI/SNF complexes become specif-
ically and differentially reliant on ARID1B (Helming et al., 2014).
ARID1A and ARID1B are 60% identical in protein sequence
and are mutually exclusive, since individual SWI/SNF chromatin
remodeling complexes can contain either ARID1A or ARID1B but
not both. Experiments aimed at validating results from the de-
pendency screen showed that knocking down ARID1B specif-
ically impaired the proliferation of ARID1A mutant cancer cells
but had minimal effect on ARID1A wild-type cancer cells. Mech-
anistically, while loss of ARID1B had no effect on integrity of SWI/
SNF complexes in wild-type cells, in the context of ARID1A
mutation, the combined absence of ARID1A and ARID1B desta-
bilized SWI/SNF complexes and resulted in dissociation of sub-
units, which was associated with loss of cell proliferation.
In SMARCA4 mutant cells in the Achilles screen, SMARCA2
was found to be specifically essential (Wilson et al., 2014), a rela-
tionship that was simultaneously and independently identified in
another screen (Hoffman et al., 2014) and an earlier focused study
in which the effects of SMARCA2 loss on SMARCA4mutant can-
cers were directly tested (Oike et al., 2013). Collectively, these re-
ports suggest that the residual complexes created by SMARCA4
mutation rely on SMARCA2 as the remaining SWI/SNF ATPase
subunit and thus cannot tolerate loss of SMARCA2. Notably, an
aspect of the synthetic lethal relationship between SMARCA4
andSMARCA2 isdistinct from thatbetweenARID1AandARID1B.
While ARID1B loss destabilizes SWI/SNF complexes in ARID1A
mutant cancers (Helming et al., 2014), the residual complexes
remain intact following SMARCA2 loss in SMARCA4mutant can-
cers (Hoffman et al., 2014; Wilson et al., 2014). This finding sug-
gests that, even though SWI/SNF subunits can fully associate
without a catalyticATPase subunit, theATPaseactivity is required
for the proliferation of the cancer cells. Collectively, these recent
findings indicate that residual complexes exist in a variety of
SWI/SNF mutant cancers and are essential for their growth.
While the dependency findings establish an essential role for
residual SWI/SNF complexes in SWI/SNF mutant cancers, the
mechanism by which these residual complexes promote cancer
remains poorly understood. One conceptual possibility is that
the residual complexes essentially acquire neomorphic gain
of function, which alters targeting and/or remodeling and results
in gene expression changes that facilitate transformation.
Perhaps consistent with such a possibility, ARID1A and ARID1B
have been reported to have opposing roles in regulation of pro-
liferation in osteoblasts (Nagl et al., 2007). Consequently, loss
of ARID1A may result in excessive incorporation of ARID1B
and unbalanced regulation of proliferation versus differentiation.
Similarly, SMARCA4 and SMARCA2 show differential expres-
sion patterns during development (Machida et al., 2001; Singh
and Archer, 2014; Zheng et al., 2004), with SMARCA4 tending
to be highly expressed in proliferating cells while SMARCA2
tends to be expressed in slowly cycling cells such as stem cells
and in noncycling differentiated cells (Reisman et al., 2009).
SMARCA4 and SMARCA2 have also been shown to interact
with different transcription factors (Kadam and Emerson, 2003)
and have been implicated in the differential control of cell fate
(Flowers et al., 2009; Zhang et al., 2011). In the neomorphic
gain-of-function model, loss of function of SWI/SNF tumorCancer Cell 26, September 8, 2014 ª2014 Elsevier Inc. 311
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residual SWI/SNF complexes. Accordingly, cancers become
addicted to the residual complex resulting in differential depen-
dency on specific subunits compared to normal cells.
The precise mechanism by which residual mutant SWI/SNF
complexes contribute to oncogenesis remains an active area
of investigation. It will be of interest to understand whether mu-
tation of SWI/SNF subunits in cancer results in mistargeting of
the complexes to chromatin akin to the effects of altered methyl-
ation of the SMARCC1 subunit, which affect targeting of SWI/
SNF complexes in breast cancer (Wang et al., 2014a). It will
also be important to determine whether the oncogenic effect of
SWI/SNF subunit mutations arises in part from altered balance
of variant SWI/SNF complexes and, furthermore, whether resid-
ual SWI/SNF complexes can properly remodel chromatin once
they are bound. Additionally, as suggested by the fascinating
finding that the SS18-SSX fusion functions primarily by ejecting
SMARCB1 from SWI/SNF complexes (Kadoch and Crabtree,
2013), a key question is whether the cancer-associated muta-
tions, in part, function by altering assembly of residual com-
plexes. A major hope is that a deeper understanding of the
mechanisms of mutant SWI/SNF complexes may facilitate
development of targeted therapeutics.
A Surprise: Comutations
Several pieces of data suggest that such a model may be too
simple. While ARID1A is perhaps the most frequently mutated
SWI/SNF subunit, mutations of ARID1B have also been found
in cancer (Kadoch et al., 2013; Sausen et al., 2013; Shain and
Pollack, 2013). Given the finding of a synthetic lethal relationship
between ARID1A inactivation and ARID1B knockdown, the pre-
diction was that the mutation of ARID1A and ARID1B would not
co-occur in the same cell line or tumor sample. Indeed, this hy-
pothesis would seem to be a fundamental prediction of synthetic
lethality: comutations should not occur. However, precisely the
opposite was found: significant co-occurrence of ARID1A and
ARID1B mutations, both in cancer cell lines and in primary can-
cers (Helming et al., 2014). What might account for both syn-
thetic lethality and comutation? One possibility is that mutations
in ARID1A or ARID1B, rather than leading to neomorphic gain of
function, result in hypofunction of the residual complexes. In this
scenario, ARID1A and ARID1B would have redundant functions
with respect to tumor suppression, and, akin to the concept of
haploinsufficiency, reduced levels of ARID1—whether ARID1A
or ARID1B—result in impaired control of gene expression and
predispose to transformation. However, retaining some amount
of ARID1 function may be essential for cell survival; conse-
quently, these mutations also result in enhanced dependence
on ARID1B compared to normal cells. The mutational profile of
ARID1A and ARID1B may provide support for such a model,
as cancer cell lines were identified that had biallelic mutations
in ARID1A in which ARID1B was either wild-type or mutant on
one allele; cancer cell lines were identified with monoallelic mu-
tations in both ARID1A and ARID1B; and, rarely, cancer cell lines
were identified in which a monoallelic mutation in ARID1A was
accompanied by biallelic mutations in ARID1B. However, no
cancer cell lines were identified in which ARID1A and ARID1B
both contained biallelic mutations consistent with an essential
role for some ARID1 function.312 Cancer Cell 26, September 8, 2014 ª2014 Elsevier Inc.The situation is less clear for the relationship between
SMARCA4 and SMARCA2. Mutations in SMARCA4 have been
reported in several types of cancer (Fukuoka et al., 2004; Medina
et al., 2008; Reisman et al., 2003) and mice haploinsufficient for
SMARCA4 are predisposed to mammary tumors (Bultman et al.,
2008). In contrast, SMARCA2 mutations are rare in primary
tumors. Sequencing of SMARCA2 in non-melanomatous skin
cancers identified a hotspot missense mutation in 3 of 16 cases
(Moloney et al., 2009), a mutation class often associated with
gain-of-function effects, although this mutation was not reported
as significant in a subsequent exome study (Jayaraman et al.,
2014). Lack of SMARCA2 expression has been noted in several
cancer cell lines and primary cancers (Glaros et al., 2007), an
effect challenging to interpret as in normal tissues SMARCA2
tends to be low in cells with high proliferative potential (Reisman
et al., 2005). However, while Smarca2-deficient mice have not
been reported prone to spontaneous tumors, they are 15%
larger than control littermates, prone to prostate hyperplasia
(Shen et al., 2008), and have increased susceptibility to tumor
formation in an ethylcarbamate lung cancer model (Glaros
et al., 2007) and a UV irradiation skin cancer model (Halliday
et al., 2012). Ultimately, while not frequently mutated, it is
possible that SMARCA2may have tumor suppressor capabilities
in human tissues. Interestingly, some cell lines and cancers have
been reported, such as the SW-13 cancer cell line, in which
SMARCA4 is mutated and SMARCA2 not expressed (Dunaief
et al., 1994; Strobeck et al., 2002). Whether such cancers reflect
emergence of resistance or whether the synthetic lethal relation-
ship is in some way context dependent is unclear and an active
area of investigation.
Therapeutic Potential
The synthetic lethal relationships described earlier raise poten-
tial opportunities for targeting of residual SWI/SNF complexes
as a therapeutic approach for cancers with a SWI/SNF muta-
tion (Figure 2). SMARCA2 contains two domains of particular
note with respect to the potential for therapeutic targeting: a bro-
modomain and an ATPase domain (Wu et al., 2009). Substantial
precedence has emerged for targeting of bomodomains, as
the JQ1 BRD4 bromodomain inhibitor (Filippakopoulos et al.,
2010) has shown promising effects in preclinical studies and clin-
ical trials of BRD4 inhibition are now in progress (http://www.
cancer.gov/clinicaltrials/search/view?cdrid=733416&version=
HealthProfessional&protocolsearchid=12562170). A similar
approachmay be feasible for SMARCA2.While the crystal struc-
tures of the bromodomains of both SMARCA4 and SMARCA2
have been solved (Filippakopoulos et al., 2012), further studies,
such as small molecule screening, will be necessary to deter-
mine if these domains are targetable. It is important to note, how-
ever, that it is not entirely clear whether the bromodomain is
essential for the function of SMARCA2, as studies have shown
that SMARCA2 activity is dependent on a high-mobility-group
protein I/Y-like DNA binding domain (Bourachot et al., 1999).
Alternatively, the ATPase domain of SMARCA2 could be tar-
geted. While structures of yeast SWI/SNF complexes have
been reported (Kasten et al., 2011), structure of the mammalian
complexes and ATPase domains would be useful for evaluating
the potential for targeted drug development. If targetable,
SMARCA2 may be a promising target, as Smarca2 knockout
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Figure 2. Residual SWI/SNF Complexes Are a
Vulnerability in Cancers Containing SWI/SNF
Subunit Mutation
Mutation of a gene encoding a SWI/SNF complex
subunit results in the formation of a residual complex
that is specifically dependent on other subunits and
essential for the growth of the cancer. Targeting
subunits of this residual complex is a newly identi-
fied therapeutic opportunity.
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mutations of SMARCA2 have been found in some neural disor-
ders (Ronan et al., 2013). A recurrent SMARCA2missensemuta-
tion has been identified in schizophrenia, where it is reported to
reduce nuclear localization of SMARCA2 protein (Koga et al.,
2009). Mutations of SMARCA2 have also been identified as the
basis for the human developmental disorder Nicolaides-Bar-
aitser syndrome (NBS) (Van Houdt et al., 2012). However, these
mutations are either missense or small in-frame deletions, and
never inactivating, leading to the prediction that the SMARCA2
mutations in NBS are gain of function and thus likely not predic-
tive of the effects of targeted inhibition.
One challenge in developing an inhibitor to SMARCA2 is its ho-
mology to SMARCA4, which may make it difficult to develop a
compound that inhibits SMARCA2 but not SMARCA4. As noted
earlier, SMARCA4 and SMARCA2 do display differential tran-
scription factor interactions, in part due to structural differences
(Kadam and Emerson, 2003), but it remains to be determined
whether such structural differences can be effectively exploited
for targeting. It is also worthy of note that three recent publica-
tions identified SMARCA4 itself as a potential therapeutic target
in small cell lung cancer (Romero et al., 2014) and in Myc-driven
leukemias (Buscarlet et al., 2014; Shi et al., 2013). On the
surface, this would seem a paradox—SMARCA4 having tumor
suppressor activity in some contexts but specifically required
for cancer maintenance in others. However, increasing data
highlight the importance of context-dependent control of gene
expression in cancer. For example, gain-of-function mutations
of EZH2 are found in lymphomas (McCabe et al., 2012), while
loss-of-function mutations occur in myelodysplastic syndromeCancer Cell 26,(Nikoloski et al., 2010). Even the canonical
tumor suppressor p53, which can promote
cancer via loss of function, is also associ-
ated with recurrent point mutations in can-
cer, some of which have been implicated
as having gain-of-function oncogenic
activity (van Oijen and Slootweg, 2000;
Strano et al., 2007). Consequently, context
is essential, and whether therapeutic
benefit might be derived from targeting
SMARCA2, SMARCA4, or both remains
to be determined.
The relationship between ARID1A and
ARID1Bmight also present therapeutic op-
portunity, as ARID1A is frequently mutated
in many human cancers. A recent finding
shows that stapled peptides can success-
fully disrupt the protein-protein interaction
between EZH2 and the Polycomb PRC2chromatin-modifying complex (Kim et al., 2013), and an analo-
gous strategy might be possible to disrupt the interaction
between ARID1B and SWI/SNF complexes. ARID1B has also
been associated with an E3 ubiquitin ligase that mediates the
monoubiquitination of histone H2B (Li et al., 2010). Targeting
the E3 ligase-associated activity of ARID1B is an approachworth
considering, although it is unknownwhether the E3 ligase activity
plays a role in the synthetic lethality.
Several potential limitations must be considered for therapeu-
tic targeting of residual SWI/SNF complexes. One is therapeutic
window. The results of recent screens suggest that, at least in
some cases, there is differential dependence on residual com-
plex members between mutant and nonmutant cells. Whether
this difference is great enough to constitute an effective thera-
peutic window, however, remains to be determined. There are
also likely to be challenges in drug development, in both identi-
fying essential domains and determining whether those domains
can be feasibly targeted. An additional concern, given the tumor
suppressor activity of several SWI/SNF subunit genes, is
whether inhibition of SWI/SNF complexes might actually cause
cancer. Even when considering ARID1B, in general, SWI/SNF
mutant cancer cell lines remain dependent on the absence of
the missing subunit. For example, reexpression of SMARCB1
in SMARCB1mutant cancers causes cell cycle arrest (Kuwahara
et al., 2010) and reexpression of SMARCA4 in SMARCA4mutant
cancers results in reversion of malignant phenotype (Romero
et al., 2012; Wong et al., 2000). Consequently, it seems likely
that, should treatment with a compound that inhibits a SWI/
SNF subunit result in the formation of a cancer, such a cancer
would likely remain dependent on the absence of the subunitSeptember 8, 2014 ª2014 Elsevier Inc. 313
Cancer Cell
Reviewand that cessation of the inhibitor would be predicted to result in
resolution of such a tumor.
Ultimately, for cancers driven by mutation of a gene encoding
a SWI/SNF subunit, at least some of these mutations result in
specific dependence on residual complex members, which in
turn, may offer potential therapeutic targets (Figure 2). Given
the large number of cancers harboring SWI/SNF mutations,
investigation of the dependency mechanisms and of the
potential to target these complexes has possible broad cancer
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